Overview: SLC35C1 Mutation TestIntroduction: The SLC35C1 Mutation Test tests for SLC35C1 gene mutations to diagnose congenital disorders of glycosylation, causing developmental delays, aiding in genetic diagnosis. Affecting 1 in 100,000 people, congenital disorders of glycosylation pose diagnostic challenges due to diverse symptoms. Following 2023 National Organization for Rare Disorders (NORD) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in genetics.
Other Names: SLC35C1 Mutation Test, CDG Gene Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: SLC35C1 testing began in the 2000s with research by Luhn, who identified the mutation. PCR/sequencing advancements by Illumina improved detection, surpassing earlier linkage analysis.
Purpose: Detects SLC35C1 mutation status to diagnose congenital disorders of glycosylation, guides supportive care or therapy, and evaluates patients with developmental delays, aiming to manage symptoms.
Test Parameters: SLC35C1 mutation status
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of developmental issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document developmental delays. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., organ failure), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect mutations, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive mutation confirms congenital disorders of glycosylation, guiding care. Early management might improve development, while untreated cases lead to worsening. Normal results may require other tests.
Specialist Consultation: Consult a geneticist or metabolic specialist for interpretation.
Additional Supporting Tests: Transferrin isoforms, enzyme assays, or genetic panel to confirm diagnosis.
Test Limitations: Specific to SLC35C1; correlation with clinical status needed. False negatives possible with other mutations.
References: NORD Guidelines, 2023; Journal of Clinical Investigation, Luhn K, 2022.
